Las Vegas Sands vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Las Vegas Sands Asia integrated resorts (NYSE: LVS) $11.4B FY2024 revenue; Sands China Macau $8.2B, Marina Bay Sands Singapore $2.93B (+14%), Londoner Macao renovation, competing with Galaxy and Melco.
About
Las Vegas Sands Corp. is a Las Vegas, Nevada-based integrated resort developer and operator — publicly traded on the New York Stock Exchange (NYSE: LVS) as an S&P 500 Consumer Discretionary component — developing, owning, and operating luxury integrated resort destinations in Macau, China (through Sands China Ltd., 69.4% owned subsidiary listed on Hong Kong Stock Exchange) and Singapore (Marina Bay Sands) through approximately 40,000 employees, following the 2021 sale of its Las Vegas properties (The Venetian, Palazzo, Las Vegas Sands Expo Center) to Apollo Global Management for $6.25 billion. In fiscal year 2024, Las Vegas Sands reported revenues of $11.4 billion (+5.7% year-over-year), with Macao Operations generating $8.2 billion ($4.49B at The Venetian Macao, $2.0B at Sands Macao, Four Seasons Macao, Parisian Macao, and Londoner Macao) and Singapore's Marina Bay Sands generating $2.93 billion (+14.3%). CEO Robert Goldstein leads Las Vegas Sands' strategy of Macau portfolio renovation and Singapore expansion: the Londoner Macao renovation ($2 billion+ investment transforming the former Sands Cotai Central into the Londoner Macao resort) completed its final tower renovations in 2024, while the Marina Bay Sands Tower 3 expansion (adding 1,000 hotel rooms, additional gaming floors, and a new arena for concerts and events) received Singapore government approval targeting 2028 completion.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.